The U.S. Food and Drug Administration approved Vanda Pharmaceuticals’ oral drug Nereus (tradipitant), marking the first new pharmacologic treatment for motion sickness in over four decades. The decision was based on three pivotal studies, including two phase III trials that tested patients in real-world maritime conditions. Vanda plans a commercial launch in early 2026 and the approval triggered a rapid market reaction reflected in the company’s stock.